检索结果-南通市图书馆

Systemic and dynamic immune landscape of Omicron-infected subjects treated with Lianhua Qingwen capsules

ACTA PHARMACEUTICA SINICA B 2024年第11期14卷 5074-5078页

作者： Chen, Shijun Wang, Fuxiang Lin, Yuanlong Xie, Yinyin Zhang, Rui-hong Chen, Juan Qiao, Niu Yin, Tong Tan, Yun Fang, Hai Lu, Hongzhou Chen, Zhu Yu, Shanhe Zhu, Jiang Jia, Zhenhua Chen, Saijuan Shanghai Jiao Tong Univ Shanghai Inst Hematol Natl Res Ctr Translat Med Shanghai Collaborat Innovat Ctr HematolRuijin HospSch Med Shanghai 200025 Peoples R China Southern Univ Sci & Technol Peoples Hosp Shenzhen 3 Natl Clin Res Ctr Infect Dis Dept Infect Dis Shenzhen 518112 Peoples R China Southern Univ Sci & Technol Affiliated Hosp 2 Shenzhen 518112 Peoples R China hebei acad integrated tradit chinese & western med Shijiazhuang 050035 Peoples R China Natl Key Lab Innovat & Transformat Luobing Theory Shijiazhuang 050035 Peoples R China

To the Editor:The COVID-19 has represented an unexpected global public health challenge due to the profound immune evasion and transmission capabilities of the responsible virus SARS-CoV-21,being in great short of effective prophylactic and curative *** Qingwen(LHQW)capsule,a traditional chinese medicine(TCM)formula,is officially included in China's COVID-19 treatment guidelines and has shown antiviral activity in vitro and in *** clinical trials have shown that LHQW can alleviate symptoms and accelerate recovery in Omicron-infected *** immune pathology of COVID-19 involves a complex interplay between virus-induced injuries and multifactorial immune ***,a comprehensive analysis of the immunological basis of LHQW's effects in Omicron-infected subjects is still lacking.

关键词： chinese traditional medicine Immune landscape COVID-19 LHQW capsule

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice： 1-year follow-up of the SERY-I registry

引用

chinese medical Journal 2011年第21期000卷 3521-3526页

作者： Zhang Rui-yan Zhang Qi Zhu Jin-zhou Chen Liang-long Zhang Chen-yun Zhou Xu-chen Yuan Yong Zhong Zhi-xiong Li Lang Qiu Jian Wang Wei Chen Xi-ming Yang Zhi-jian Yan Jin-chuan Chen Shao-liang Hou Yu-qing Wu Yan-qing Luo Hai-ming Qiu Jian-ping Zhu Li Wang Yan Fu Guo-sheng Wang Jian-an Ma Kang-hua Yin Yue-hui Zhang Dai-fu Hu Xue-song Zhu Guo-ying Shen Wei-feng Shanghai Jiao Tong Univ Sch Med Dept Cardiol Ruijin Hosp Shanghai 200025 Peoples R China Fujian med Univ Union Hosp Dept Cardiol Fuzhou 350005 Fujian Peoples R China Guizhou Prov Peoples Hosp Dept Cardiol Guiyang 550002 Guizhou Peoples R China Dalian med Univ Affiliated Hosp 1 Dept Cardiol Dalian 116011 Liaoning Peoples R China Zhongshan Peoples Hosp Dept Cardiol Zhongshan 528400 Guangdong Peoples R China Meizhou Peoples Hosp Dept Cardiol Meizhou 514031 Guangdong Peoples R China Guangxi med Univ Affiliated Hosp 1 Dept Cardiol Nanning 530000 Guagnxi Peoples R China Gen Hosp Guangzhou Mil Command Peoples Liberat Ar Dept Cardiol Guangzhou 510010 Guangdong Peoples R China Guangzhou med Coll Dept Cardiol Affiliated Hosp 1 Guangzhou 510120 Guangdong Peoples R China Guangzhou med Coll Dept Cardiol Affiliated Hosp 3 Guangzhou 510150 Guangdong Peoples R China Jiangsu Prov Hosp Dept Cardiol Nanjing 210029 Jiangsu Peoples R China Jiangsu Univ Dept Cardiol Affiliated Hosp Zhenjiang 212001 Jiangsu Peoples R China Nanjing First Hosp Dept Cardiol Nanjing 210000 Jiangsu Peoples R China So med Univ Dept Cardiol Nanfang Hosp Guangzhou 510515 Guangdong Peoples R China Nanchang Univ Dept Cardiol Affiliated Hosp 2 Nanchang 330006 Jiangxi Peoples R China Shanghai Univ tradit chinese med Dept Cardiol Yueyang Hosp Integrated Tradit Chinese & Western Shanghai 200437 Peoples R China Shanghai Pudong New Area Goughli Hosp Dept Cardiol Shanghai 200135 Peoples R China Jiangsu Taizhou Peoples Hosp Dept Cardiol Taizhou 225300 Jiangsu Peoples R China Xiamen Univ Dept Cardiol Zhongshan Hosp Xiamen 361004 Fujian Peoples R China Sir Run Run Shaw Hosp Dept Cardiol Hangzhou 310020 Zhejiang Peoples R China Zhejiang Univ Sch Med Dept Cardiol Affiliated Hosp 2 Hangzhou 310009 Zhejiang Peoples R China Chongqing med Univ Dept Cardiol Affiliated Hosp 1 Chongqing 400042 Peoples R China Chongqing med Univ Dept Cardiol Affiliated Hosp 2 Chongqing 400010 Peop

Background Polymer coating on coronary stents induces vascular inflammatory response, reduces re-endothelialization, and affects long-term outcome after percutaneous coronary intervention （PCI）. The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice. Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of 〉1 Yinyi stents between June 2008 and August 2009 at 27 medical centers. The primary endpoint was the cumulative rate of composite major adverse cardiac events （MACE） and the secondary endpoint was the incidence of stent thrombosis at 1 year. Results Overall, 1376 lesions were treated successfully with 1713 Yinyi stents, and 1019 （98.7%） patients received dual antiplatelet therapy for at least 12 months. During 1-year follow-up, 8 patients （0.78%） had cardiac death, 6 （0.58%） suffered non-fatal myocardial infarction, and 46 （4.46%） underwent repeat PCI due to recurrence of angina, resulting in 1-year MACE-free survival of 94.09%. Stent thrombosis occurred in 10 （0.97%） patients, and the rate of academic Research Consortium （ARC） definite or probable stent thrombosis was 0.78%. Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice, without recourse to carrier polymer. Potential long-term clinical advantages of this stent deserve further investigation.

关键词： polymer-free microporous stent paclitaxel-eluting stent stent thrombosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Study on the prognostic factors of Graves'disease treated with antithyroid drugs

引用

China medical Abstracts(Internal medicine) 2022年第1期39卷 23-23页

作者： CUI Wenjin Jiansu Prov TCM acad Dept EndocrinolAffil HospIntegr Trad Chin&West MedNanjing CM UnivNanjing 210028

Objective To investigate the risk factors for recurrence of Graves’ disease after withdrawal of antithyroid drugs(ATD).Methods This prospective study recruited 285 patients with newly onset Graves'disease taking ATD from 2012 to 2018 at Department of Endocrinology,Affiliated Hospital of integrated traditional chinese and western medicine.A total of 121 patients who completed follow-up were enrolled and were divided into relapse and remission group according to whether hyperthyroidism reoccurred within 2 years after ATD withdrawal.

关键词： drugs Graves patients

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：